IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
35.1%
Sector: -43.5%
Dividend Analysis audit
INCOME
3.89%
Trailing Yield
$3.89
Per $100 Invested
Solid dividend yield for income-focused strategies.
Est. Payout Ratio
62%MID
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Merck & Co., Inc. (MRK) receives a "Hold" rating with a composite score of 53.5/100, ranked #314 out of 4446 stocks. Key factor scores: Quality 50/100, Value 66/100, Momentum 61/100. This is quantitative analysis only — not investment advice.
Merck & Co., Inc. (MRK) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Merck & Co., Inc. Do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co., Inc. (MRK) is classified as a mega-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert M. Davis and employs approximately 69,000 people, headquartered in KENILWORTH, New Jersey. With a market capitalization of $298.8B, MRK is one of the largest companies in the Healthcare sector.
Merck & Co., Inc. (MRK) Stock Rating — Hold (April 2026)
As of April 2026, Merck & Co., Inc. receives a Hold rating with a composite score of 53.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.MRK ranks #314 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Merck & Co., Inc. ranks #12 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MRK Stock Price and 52-Week Range
Merck & Co., Inc. (MRK) currently trades at $120.73. The stock lost $1.95 (1.6%) in the most recent trading session. The 52-week high for MRK is $125.14, which means the stock is currently trading -3.5% from its annual peak. The 52-week low is $73.31, putting the stock 64.7% above its annual trough. Recent trading volume was 9.7M shares, reflecting moderate market activity.
Is MRK Overvalued or Undervalued? — Valuation Analysis
Merck & Co., Inc. (MRK) carries a value factor score of 66/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 15.97x, compared to the Healthcare sector average of 23.63x — a discount of 32%. The price-to-book ratio stands at 5.60x, versus the sector average of 2.75x. The price-to-sales ratio is 4.52x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MRK trades at 13.57x EV/EBITDA, versus 6.34x for the sector.
Overall, MRK's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Merck & Co., Inc. Profitability — ROE, Margins, and Quality Score
Merck & Co., Inc. (MRK) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 35.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 13.5% versus the sector average of -33.1%.
On a margin basis, Merck & Co., Inc. reports gross margins of 77.2%, compared to 71.5% for the sector. The operating margin is 33.3% (sector: -66.1%). Net profit margin stands at 28.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 7.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
MRK Debt, Balance Sheet, and Financial Health
Merck & Co., Inc. has a debt-to-equity ratio of 160.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.54x, suggesting adequate working capital coverage. Total debt on the balance sheet is $41.37B. Cash and equivalents stand at $18.17B.
MRK has a beta of 0.48, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Merck & Co., Inc. is 82/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
Merck & Co., Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Merck & Co., Inc. reported revenue of $65.27B and earnings per share (EPS) of $7.30. Net income for the quarter was $18.46B. Gross margin was 77.2%. Operating income came in at $21.74B.
In FY 2025, Merck & Co., Inc. reported revenue of $65.01B and earnings per share (EPS) of $7.30. Net income for the quarter was $18.26B. Gross margin was 74.8%. Revenue grew 1.3% year-over-year compared to FY 2024. Operating income came in at $21.07B.
In Q3 2025, Merck & Co., Inc. reported revenue of $17.28B and earnings per share (EPS) of $2.32. Net income for the quarter was $5.79B. Gross margin was 77.7%. Revenue grew 3.7% year-over-year compared to Q3 2024. Operating income came in at $6.75B.
In Q2 2025, Merck & Co., Inc. reported revenue of $15.81B and earnings per share (EPS) of $1.76. Net income for the quarter was $4.43B. Gross margin was 77.5%. Revenue grew -1.9% year-over-year compared to Q2 2024. Operating income came in at $5.00B.
Over the past 8 quarters, Merck & Co., Inc. has demonstrated a growth trajectory, with revenue expanding from $16.11B to $65.27B. Investors analyzing MRK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MRK Dividend Yield and Income Analysis
Merck & Co., Inc. (MRK) currently pays a dividend yield of 3.9%. At this yield, a $10,000 investment in MRK stock would generate approximately $$389.00 in annual dividend income. With a net margin of 28.3%, the dividend appears well-covered by earnings, suggesting sustainable payouts going forward.
MRK Momentum and Technical Analysis Profile
Merck & Co., Inc. (MRK) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 21/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
MRK vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing MRK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MRK vs S&P 500 (SPY) comparison to assess how Merck & Co., Inc. stacks up against the broader market across all factor dimensions.
MRK Next Earnings Date
No upcoming earnings date has been announced for Merck & Co., Inc. (MRK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MRK? — Investment Thesis Summary
Merck & Co., Inc. presents a balanced picture with arguments on both sides. The value score of 66/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 61/100, suggesting the trend favors buyers. Low volatility (stability score 82/100) reduces downside risk.
In summary, Merck & Co., Inc. (MRK) earns a Hold rating with a composite score of 53.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MRK stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
Merck & Co., Inc. (MRK) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
We maintain our Hold rating on Merck (MRK), driven by a balanced view of its strong oncology franchise, particularly Keytruda, and its robust animal health business, offset by concerns regarding future revenue diversification as Keytruda approaches patent expiration. While Merck exhibits strong profitability and returns compared to the healthcare sector, its recent negative free cash flow and high debt-to-equity ratio warrant caution. The current valuation appears fair, reflecting both its growth prospects and inherent risks.
Merck's strategic focus on oncology and vaccines, coupled with its animal health segment, provides a diversified revenue stream. However, the heavy reliance on Keytruda exposes the company to significant revenue decline upon loss of exclusivity. The company's investment in research and development and strategic collaborations are crucial for long-term growth, but the success of these initiatives remains uncertain. Therefore, a Hold rating is appropriate, reflecting a neutral stance on the stock's near-term performance.
Business Strategy & Overview
Merck operates as a global healthcare company with two primary segments: Pharmaceutical and Animal Health. The Pharmaceutical segment focuses on developing and commercializing human health products, with a strong emphasis on oncology, vaccines, and other therapeutic areas. Keytruda, its blockbuster oncology drug, is a major revenue driver, and the company continues to expand its indications and market reach. The vaccine portfolio includes preventive pediatric, adolescent, and adult vaccines, contributing significantly to overall revenue.
The Animal Health segment discovers, develops, and markets veterinary pharmaceuticals, vaccines, and health management solutions. This segment provides diversification and growth opportunities, benefiting from the increasing demand for animal health products globally. Merck's strategy involves investing in research and development to discover new drugs and vaccines, expanding existing product lines, and pursuing strategic collaborations to enhance its pipeline and market access.
Merck's strategic positioning revolves around innovation and market leadership in key therapeutic areas. The company invests heavily in R&D to develop novel therapies and expand the indications of existing products. Strategic collaborations with companies like AstraZeneca, Bayer, and Eisai are crucial for co-developing and commercializing new treatments, particularly in oncology and HIV. These collaborations allow Merck to leverage external expertise and resources, accelerating the development and commercialization process.
Merck's product pipeline includes a range of investigational drugs and vaccines in various stages of development. The company is focused on advancing its pipeline through clinical trials and regulatory approvals, with the goal of launching new products and expanding its market presence. The success of its pipeline is critical for mitigating the impact of patent expirations and maintaining long-term growth. The company's business model relies on a combination of internal research and development, strategic collaborations, and acquisitions to drive innovation and growth.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
7.2%
Sector: 10.6%
-32% VS SCTR
Economic Moat Analysis
Merck possesses a Narrow economic moat, primarily derived from intangible assets and, to a lesser extent, switching costs in certain areas of its animal health business. The intangible assets stem from its patented drug formulations, particularly Keytruda, and the brand recognition associated with its vaccine portfolio. These patents provide temporary exclusivity, allowing Merck to generate significant profits before generic competition erodes market share. However, the limited duration of patent protection and the eventual entry of biosimilars and generics constrain the moat's width.
Keytruda's dominance in the oncology market is a significant source of competitive advantage, but its reliance on a single drug also represents a vulnerability. While Merck is actively pursuing new indications and combination therapies for Keytruda, the eventual loss of exclusivity will inevitably impact its revenue stream. The company's ability to develop and commercialize new blockbuster drugs will be crucial for maintaining its competitive position.
In the Animal Health segment, Merck benefits from some degree of switching costs, particularly in livestock and companion animal health management solutions. Veterinarians and animal producers often develop long-term relationships with suppliers and are reluctant to switch to new products or services unless there is a significant cost or performance advantage. However, these switching costs are not insurmountable, and competitors can gain market share by offering innovative or more cost-effective solutions.
Merck's research and development capabilities are a key driver of its competitive advantage. The company invests heavily in R&D to discover and develop new drugs and vaccines, which can provide a temporary period of market exclusivity. However, the pharmaceutical industry is highly competitive, and there is no guarantee that Merck's R&D investments will consistently yield successful products. The company's ability to maintain a strong pipeline of innovative therapies is essential for sustaining its narrow economic moat.
Financial Health & Profitability
Merck demonstrates strong profitability compared to the healthcare sector, with a TTM net margin of 28.3% versus the sector's -54.1%. Its gross margin of 77.2% and operating margin of 33.3% also significantly outperform the sector averages of 71.9% and -65.2%, respectively. The company's ROE of 35.1% is substantially higher than the sector's -42.5%, indicating efficient use of equity to generate profits. These metrics highlight Merck's ability to generate strong earnings from its operations.
However, Merck's free cash flow (FCF) is currently negative at $-904.20 million, which is a concerning trend. This could be due to increased investments in R&D, acquisitions, or other factors. While the company has a substantial cash balance of $18.17 billion, the negative FCF raises questions about its ability to fund future growth and shareholder returns. Monitoring the FCF trend is crucial to assess the company's long-term financial health.
Merck's debt-to-equity ratio is relatively high at 160.00, compared to the sector average of 30.00. This indicates a higher level of financial leverage, which can increase financial risk. While the company has a strong cash position, managing its debt levels is important to maintain financial stability. The current ratio of 1.54 suggests that Merck has sufficient current assets to cover its current liabilities.
Analyzing the quarterly financial history reveals consistent revenue growth, with revenue increasing from $60.12 billion in FY2023 to $65.01 billion in FY2025. Net income has also shown improvement, although it was significantly lower in FY2023 due to certain charges. Gross margins have remained relatively stable, while operating margins have fluctuated, reflecting changes in operating expenses. Overall, Merck's financial performance has been strong, but the negative FCF and high debt levels warrant close monitoring.
Valuation Assessment
Merck's valuation appears fair based on its current multiples. The company's P/E ratio of 15.6x is lower than the healthcare sector average of 24.3x, suggesting that it may be undervalued relative to its peers. Similarly, its EV/EBITDA ratio of 3.4x is significantly lower than the sector average of 6.4x, further supporting the notion of undervaluation. However, these multiples should be considered in the context of Merck's growth prospects and risk profile.
Given Merck's strong profitability and returns, a lower P/E ratio might be justified if the market anticipates a slowdown in growth or increased competition. The impending patent expiration of Keytruda is a significant factor that could weigh on the company's future earnings. Therefore, the market may be discounting Merck's valuation to reflect this risk.
A discounted cash flow (DCF) analysis would provide a more comprehensive valuation assessment, but without detailed projections, it is difficult to determine the intrinsic value of the stock. However, based on the available data, Merck's current valuation seems reasonable, reflecting a balance between its growth potential and inherent risks. The Hold rating is consistent with this assessment.
Compared to its historical valuation, Merck's current multiples are within a reasonable range. The company's P/E ratio has fluctuated over time, reflecting changes in its earnings and market sentiment. The current P/E ratio is slightly below its historical average, suggesting that the stock is not overvalued. However, it is important to consider the company's future growth prospects and risk factors when assessing its valuation.
Risk & Uncertainty
Merck faces several specific risks that could impact its business and financial performance. The most significant risk is the impending patent expiration of Keytruda, its blockbuster oncology drug. The loss of exclusivity will lead to generic competition and a substantial decline in revenue. Merck's ability to develop and commercialize new drugs to offset this revenue loss is crucial for its long-term growth.
Regulatory risks are also a significant concern for Merck. The pharmaceutical industry is heavily regulated, and changes in regulations can impact the approval and marketing of drugs. Pricing pressures from governments and healthcare providers can also affect Merck's profitability. The company must navigate these regulatory challenges to maintain its market access and pricing power.
Competition from other pharmaceutical companies is intense. Merck faces competition from established players and emerging biotech companies. The development of new and innovative therapies by competitors can erode Merck's market share. The company must continue to invest in R&D and strategic collaborations to stay ahead of the competition.
Product liability risks are inherent in the pharmaceutical industry. Merck faces the risk of lawsuits and product recalls if its drugs cause adverse effects or are found to be defective. These liabilities can result in significant financial losses and reputational damage. The company must maintain rigorous quality control and safety standards to mitigate these risks.
Bulls Say / Bears Say
The Bull Case
BULL VIEWKeytruda's continued expansion into new indications and combination therapies will drive significant revenue growth in the near term, exceeding market expectations.
BULL VIEWMerck's robust animal health business provides a stable and growing revenue stream, offsetting the potential impact of patent expirations in the pharmaceutical segment.
BULL VIEWThe company's strong pipeline of investigational drugs and vaccines will yield several blockbuster products in the coming years, driving long-term growth and shareholder value.
The Bear Case
BEAR VIEWThe impending patent expiration of Keytruda will lead to a significant revenue decline, which Merck will struggle to offset with new product launches.
BEAR VIEWMerck's high debt levels and negative free cash flow raise concerns about its financial flexibility and ability to fund future growth initiatives.
BEAR VIEWIncreased competition in the oncology market will erode Keytruda's market share and pricing power, negatively impacting Merck's profitability.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score MRK and 4,400+ other equities.
Merck & Co., Inc. exhibits a 89% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
13.5%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
77.2%
Sector: 71.5%
Operating Margin
Core business profitability
33.3%
Sector: -66.1%
Net Margin
Bottom-line profitability
28.3%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
Sector Avg Yield0.00%
Yield Delta—
Income Projection audit
A $10,000 investment would generate approximately $389 annually in dividends at the current trailing rate.
